Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group.

SARS-CoV-2 vaccine anti-spike antibody response cancer patient neutralizing IgG

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
15 Sep 2021
Historique:
received: 19 08 2021
revised: 11 09 2021
accepted: 13 09 2021
entrez: 28 9 2021
pubmed: 29 9 2021
medline: 29 9 2021
Statut: epublish

Résumé

Data on the effectiveness and safety of approved SARS-CoV-2 vaccines in cancer patients are limited. This observational, prospective cohort study investigated the humoral immune response to SARS-CoV-2 vaccination in 232 cancer patients from 12 HeCOG-affiliated oncology departments compared to 100 healthcare volunteers without known active cancer. The seropositivity rate was measured 2-4 weeks after two vaccine doses, by evaluating neutralising antibodies against the SARS-CoV-2 spike protein using a commercially available immunoassay. Seropositivity was defined as ≥33.8 Binding-Antibody-Units (BAU)/mL. A total of 189 patients and 99 controls were eligible for this analysis. Among patients, 171 (90.5%) were seropositive after two vaccine doses, compared to 98% of controls (

Identifiants

pubmed: 34572848
pii: cancers13184621
doi: 10.3390/cancers13184621
pmc: PMC8466969
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Lancet Reg Health Eur. 2021 Jul;6:100109
pubmed: 33997835
Med Oncol. 2002;19(2):71-8
pubmed: 12180483
BMC Med. 2021 Jun 28;19(1):155
pubmed: 34183003
JAMA Oncol. 2021 Aug 1;7(8):1133-1140
pubmed: 34047765
Ann Oncol. 2021 May;32(5):579-581
pubmed: 33582237
J Neuroimmune Pharmacol. 2021 Mar;16(1):38-47
pubmed: 33405098
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
Am J Hematol. 2021 Oct 1;96(10):1195-1203
pubmed: 34185336
Acta Oncol. 2014 Sep;53(9):1212-20
pubmed: 24865118
Biol Sex Differ. 2020 May 25;11(1):29
pubmed: 32450906
Ann Oncol. 2021 Oct;32(10):1294-1295
pubmed: 34171494
Med Oncol. 2021 Jul 24;38(9):101
pubmed: 34302557
Br J Haematol. 2021 Feb;192(3):467-473
pubmed: 33474730
Aging Cell. 2015 Jun;14(3):309-21
pubmed: 25720438
Ann Oncol. 2012 Feb;23(2):450-7
pubmed: 21576285
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2
pubmed: 34214473
JAMA Oncol. 2021 Jul 8;:
pubmed: 34236381
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Eur J Cancer. 2020 Nov;139:43-50
pubmed: 32971510
Cancer Biol Med. 2021 Feb 15;18(1):298-307
pubmed: 33628602
Ann Oncol. 2020 Aug;31(8):1087-1088
pubmed: 32360743
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Ann Oncol. 2021 Aug;32(8):1053-1055
pubmed: 33932508
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Lung Cancer. 2021 Jul;157:60-65
pubmed: 33985850
Diabetes Metab Res Rev. 2021 May 6;:e3465
pubmed: 33955644
J Clin Med. 2020 Dec 09;9(12):
pubmed: 33317059
Support Care Cancer. 2001 Jan;9(1):65-8
pubmed: 11147146
Cochrane Database Syst Rev. 2013 Oct 29;(10):CD008983
pubmed: 24166741
Clin Chem Lab Med. 2021 Mar 15;59(8):1463-1467
pubmed: 33711225
Science. 2020 Dec 4;370(6521):1227-1230
pubmed: 33115920
J Clin Oncol. 2019 Oct 20;37(30):2795-2804
pubmed: 31465264
Cell Immunol. 2013 Mar;282(1):38-43
pubmed: 23665673
J Immunol. 2012 Mar 1;188(5):2359-70
pubmed: 22279108
Nat Rev Immunol. 2002 May;2(5):372-7
pubmed: 12033743
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
Can J Public Health. 2020 Dec;111(6):980-983
pubmed: 32990927
Ann Hematol. 2021 Feb;100(2):383-393
pubmed: 33159569
Vaccine. 2021 Jul 22;39(32):4423-4428
pubmed: 34210573
Ann Oncol. 2021 Jan;32(1):113-119
pubmed: 33098994
Blood. 2020 Dec 17;136(25):2881-2892
pubmed: 33113551
Front Immunol. 2021 Mar 09;12:637974
pubmed: 33767708
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Signal Transduct Target Ther. 2021 Feb 2;6(1):48
pubmed: 33531462
Viruses. 2021 Feb 12;13(2):
pubmed: 33673067
Clin Infect Dis. 2021 Jan 27;72(2):351-356
pubmed: 33501958

Auteurs

Helena Linardou (H)

Fourth Oncology Department and Comprehensive Clinical Trials Centre, Metropolitan Hospital, 18547 Athens, Greece.

Nikolaos Spanakis (N)

Department of Microbiology, Medical School, National and Kapodistrian University of Athens, 11524 Athens, Greece.
AlfaLab, Hellenic HealthCare Group, 11524 Athens, Greece.

Georgia-Angeliki Koliou (GA)

Section of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, 11526 Athens, Greece.

Athina Christopoulou (A)

Medical Oncology Unit, S. Andrew Hospital, 26332 Patras, Greece.

Sofia Karageorgopoulou (S)

Third Department of Medical Oncology, IASO Clinic, 15123 Athens, Greece.

Nephely Alevra (N)

Fourth Oncology Department and Comprehensive Clinical Trials Centre, Metropolitan Hospital, 18547 Athens, Greece.

Anastasios Vagionas (A)

Oncology Department, General Hospital of Kavala, 65500 Kavala, Greece.

Nikolaos Tsoukalas (N)

Department of Oncology, 401 General Military Hospital of Athens, 11525 Athens, Greece.

Stavroula Sgourou (S)

Fourth Oncology Department and Comprehensive Clinical Trials Centre, Metropolitan Hospital, 18547 Athens, Greece.

Elena Fountzilas (E)

Second Department of Medical Oncology, Euromedica General Clinic of Thessaloniki, 54645 Thessaloniki, Greece.
European University Cyprus, Nicosia 2404, Cyprus.

Joseph Sgouros (J)

Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, 14564 Athens, Greece.

Evangelia Razis (E)

Third Department of Medical Oncology, Hygeia Hospital, 15123 Athens, Greece.

Dimitra Chatzokou (D)

AlfaLab, Hellenic HealthCare Group, 11524 Athens, Greece.

Sofia Lampaki (S)

Pulmonary Department, Lung Cancer Oncology Unit, Aristotle University of Thessaloniki, G. Papanicolaou Hospital, 57010 Thessaloniki, Greece.

Eleni Res (E)

Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, 14564 Athens, Greece.

Zacharenia Saridaki (Z)

Asklepieion Crete Clinic, Oncology Department, 71201 Heraklion, Greece.

Giannis Mountzios (G)

Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, 11526 Athens, Greece.

George Saroglou (G)

Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Internal Medicine Department, Metropolitan Hospital, 18547 Athens, Greece.

George Fountzilas (G)

Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
Department of Medical Oncology, German Oncology Center, Limassol 4108, Cyprus.

Classifications MeSH